Skip to main content


Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study

Fig. 2

Drug survival rates due to toxic adverse events in a non-adjusted cases and b adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

Back to article page